Abbott Laboratories (ABT) Stock Forecast & Price Target

$134.41 +2.35 (+1.78%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$134.40 -0.01 (0.00%)

As of 08/8/2025 07:59 PM Eastern

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 22 Analyst Ratings

Sell
0

Hold
4

Buy
18

Based on 22 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 4 have given a hold rating, 16 have given a buy rating, and 2 have given a strong buy rating for ABT.

Consensus Price Target

$144.47
7.49% Upside

According to the 22 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $144.47. The highest price target for ABT is $160.00, while the lowest price target for ABT is $130.00. The average price target represents a forecasted upside of 7.49% from the current price of $134.41.

Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

ABT Analyst Ratings Over Time

Type	Current Forecast 8/9/24 to 8/9/25	1 Month Ago 7/10/24 to 7/10/25	3 Months Ago 5/11/24 to 5/11/25	1 Year Ago 8/10/23 to 8/9/24
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)	7 Buy rating(s)
Hold	4 Hold rating(s)	6 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$144.47	$143.11	$142.59	$121.00
Forecasted Upside	7.49% Upside	7.09% Upside	6.81% Upside	11.31% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abbott Laboratories Stock vs. The Competition

Type	Abbott Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.91	2.81	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	7.49% Upside	27,881.33% Upside	13.84% Upside
News Sentiment Rating	Very Positive News See Recent ABT News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/18/2025	Wells Fargo & Company 3 of 5 stars	Lawrence Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$147.00 ➝ $142.00	+14.26%
7/18/2025	Raymond James Financial 4 of 5 stars	Jayson Bedford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$142.00 ➝ $141.00	+13.29%
7/18/2025	BTIG Research 2 of 5 stars	Marie Thibault Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$148.00 ➝ $145.00	+20.08%
7/18/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$143.00 ➝ $145.00	+20.08%
7/17/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Strong-Buy
7/16/2025	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$130.00 ➝ $140.00	+6.54%
7/15/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$145.00 ➝ $147.00	+12.31%
7/15/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Lewis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$127.00 ➝ $137.00	+3.75%
7/8/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$140.00 ➝ $145.00	+8.52%
6/16/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
Get the Latest News and Ratings for ABT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter.
6/16/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$143.00	+5.61%
4/17/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$133.00 ➝ $145.00	+9.98%
4/17/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$158.00 ➝ $159.00	+21.71%
4/17/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$135.00 ➝ $145.00	+11.76%
3/10/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Travis Steed Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$133.00 ➝ $150.00	+8.03%
3/4/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$135.00 ➝ $160.00	+15.20%
3/4/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$138.00 ➝ $154.00	+9.70%
1/28/2025	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
1/23/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$146.00 ➝ $148.00	+25.68%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$133.00 ➝ $138.00	+17.37%
10/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$130.00	+14.69%
9/19/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$131.00	+14.04%
7/30/2024	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:44 PM ET.

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, August 8, 2025. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

Abbott Laboratories has received multiple upgrades from analysts, including a "strong-buy" rating, indicating strong confidence in the company's future performance.
The current stock price is around $132, which is near its 52-week high, suggesting strong market interest and potential for further growth.
The company reported a significant increase in quarterly revenue, up 7.4% year-over-year, showcasing its ability to grow even in competitive markets.
Abbott Laboratories has a solid dividend yield of 1.8%, providing investors with a steady income stream, which is particularly attractive in uncertain economic times.
With a consensus rating of "Moderate Buy" and an average price target of approximately $144.47, analysts see potential for price appreciation, making it an appealing investment opportunity.

Abbott Laboratories
Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

Despite recent growth, the stock has a relatively low beta of 0.70, indicating lower volatility, which may not appeal to investors seeking high-risk, high-reward opportunities.
The company's debt-to-equity ratio of 0.25 suggests a conservative approach to leveraging, which might limit aggressive growth strategies that some investors prefer.
Analysts have mixed opinions, with four rating the stock as a hold, indicating some uncertainty about its short-term performance.
While the company has a strong market presence, it operates in a highly competitive healthcare sector, which could impact future growth and profitability.
Recent price target adjustments by various analysts show a range of opinions, which may create uncertainty for potential investors regarding the stock's future trajectory.

ABT Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $144.47, with a high forecast of $160.00 and a low forecast of $130.00.
: 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 4 hold ratings, 16 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABT shares.
: According to analysts, Abbott Laboratories's stock has a predicted upside of 7.49% based on their 12-month stock forecasts.
: Over the previous 90 days, Abbott Laboratories's stock had 3 upgrades by analysts.
: Abbott Laboratories has been rated by research analysts at BTIG Research, Evercore ISI, Jefferies Financial Group, Leerink Partners, Leerink Partnrs, Mizuho, Morgan Stanley, Raymond James Financial, Royal Bank Of Canada, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Abbott Laboratories more than other "medical" companies. The consensus rating score for Abbott Laboratories is 2.91 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ABT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:ABT) was last updated on 8/9/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Stock Forecast & Price Target